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ABSTRACT 
Objective 
To analyse the worldwide occurrence of sicca/Sjögren (SjS) syndrome associated with the use of 
immune checkpoint inhibitors (ICI) in patients with cancer. 
Methods 
The ImmunoCancer International Registry (ICIR) is a Big Data-Sharing multidisciplinary network 
composed by 40 specialists in Rheumatology, Internal Medicine, Immunology and Oncology from 18 
countries focused on the clinical and basic research of the immune-related adverse events (irAEs) 
related to cancer immunotherapies. For this study, patients investigating for a clinical suspicion of SjS 
after being exposed to ICI were included.  
Results 
We identified 26 patients (11 women and 15 men, with a mean age at diagnosis of 63,57 years). 
Underlying cancer included lung (n=12), renal (n=7), melanoma (n=4), and other (n=3) neoplasia. 
Cancer immunotherapies consisted of monotherapy (77%) and combined regimens (23%). In those 
patients receiving monotherapy, all patients were treated with PD1/PD1-L inhibitors (nivolumab in 9, 
pembrolizumab in 7 and durvalumab in 4); no cases associated with CTLA-4 inhibitors were identified. 
The main SjS-related features consisted of dry mouth in 25 (96%) patients, dry eye in 17 (65%), 
abnormal ocular tests in 10/16 (62%) and abnormal oral diagnostic tests in 12/14 (86%) patients. Minor 
salivary gland biopsy was carried in 15 patients: histopathological findings consisted of mild chronic 
sialadenitis in 8 (53%) patients and focal lymphocytic sialadenitis in the remaining 7 (47%); a focus 
score was measured in 5 of the 6 patients (mean of 1.8, range 1 to 4). Immunological markers included 
positive ANA in 13/25 (52%), anti-Ro/SS-A in 5/25 (20%), RF in 2/22 (9%), anti-La/SS-B in 2/25 (8%), 
low C3/C4 levels in 1/17 (6%) and positive cryoglobulins in 1/10 (10%). Classification criteria for SjS 
were fulfilled by 10 (62%) out of 16 patients in whom the two key classificatory features were carried 
out. Among the 26 patients, there were only 3 (11%) who presented exclusively sicca syndrome 
without organ-specific autoimmune manifestations. Therapeutic management included measures 
directed to treat sicca symptoms and therapies against autoimmune-mediated manifestations 
(glucocorticoids in 42%, second/third-line therapies in 31%); therapeutic response for systemic 
features was observed in 8/11 (73%). No patient died due to autoimmune involvement. 
Conclusions 
Patients with Sjögren syndrome triggered by ICI display a very-specific profile different from that 
reported in idiopathic primary SjS, including more frequent occurrence in men, a higher mean age, a 
predominant immunonegative serological profile, and a notable development of organ-specific 
autoimmune involvement in spite of the poor immunological profile. The close association found 
between sicca/Sjögren syndrome and primarily PD1 blockade requires further specific investigation. 
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INTRODUCTION 
Immunotherapies are a group of drugs designed to target specific molecules of the immune system. 
These therapies use different pharmacoimmunological approaches that may include not only the use 
of specific drugs (monoclonal antibodies, small proteins, fusion proteins) targeting proteins located on 
the surface of cancer or immune cells, but also the use of other non-specific therapies including 
cytokines, oncolytic virus therapies, cancer vaccines, or CAR T-cell therapies [1]. Among monoclonal 
antibodies, immune checkpoint inhibitors (ICIs) target different pathways that harbor 
immunosuppressive functions used by cancer cells to evade immunosurveillance, and among the ICIs, 
PD-1/PD-L1 and CTLA-4 inhibitors have showed promising therapeutic outcomes [2]. 
However, with the increasing use of ICIs the occurrence of a group of side effects referred to as 
immune-related adverse events (irAEs) is also increasingly recognized. Many of these side effects are 
driven by the same immunologic mechanisms responsible for the drugs’ therapeutic effects, namely 
the blockade of the inhibitory mechanisms that suppress the immune system and protect body tissues 
from an autoimmune damage. These irAEs are unique and different than those associated with 
cytotoxic chemotherapy, radiotherapy, or targeted therapies [3]. Immunotherapy-related irAEs 
typically have a delayed onset and prolonged duration compared to adverse events from 
chemotherapy [4]. Clinical features are important in the way of providing evidence that helps to the 
diagnosis including, in cases where possible, histological confirmation through a biopsy-proven 
evidence of autoimmune-related damage. Moreover, serological confirmation through of the presence 
of positive autoantibody testing that should be sought to clarify the nature of the autoimmune process, 
although the results may be negative in a significant number of patients. Most irAEs consisted of organ-
specific autoimmune diseases, and less frequently, systemic and rheumatic diseases [3]. The first case 
of Sjögren syndrome (SjS) triggered by cancer immunotherapies has been recently reported by Cappelli 
et al [5], with an increasing number of additional cases reported since then [6]. 
The objective of this study was to analyse the worldwide scenario of SjS associated with the use of 
cancer immunotherapies through the development of an international real-life registry of patients 
with cancer diagnosed with rheumatic and systemic autoimmune diseases using a big data network 
approach (International Immunocancer Registry Project). 
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METHODOLOGY 
The International ImmunoCancer Registry (ICIR) is a Big Data-Sharing multidisciplinary network 
composed by 40 specialists in Rheumatology, Internal Medicine, Immunology and Oncology from 18 
countries focused on the clinical and basic research of the irAEs related to cancer immunotherapies. 
The two starting objectives of the Project consisted of: 
a) A retrospective study of rheumatic and systemic autoimmune diseases triggered by cancer 
immunotherapies seen in daily practice by the ICIR members, following a descriptive, non-
interventional, data-sharing international network database design. Data were obtained by 
retrospective evaluation of medical charts by the physician on charge of the patient included 
into ongoing research projects involving local registries of irAEs (each validated for the 
corresponding local IRB). For this study, we selected patients presenting with a clinical 
suspicion of SjS after being exposed to cancer immunotherapies. Exclusion criteria included 
the concomitant use of standard chemotherapy/radiotherapy or other aetiologies directly 
related to the development of sicca symptoms. 
b) A systematic literature review (SLR) performed until April 15, 2019. We selected biologics from 
the main groups of cancer immunotherapies, which were crossed with rheumatic and systemic 
autoimmune diseases using the terms included in the Medical Dictionary for Regulatory 
Activities terminology (MedDRAVR 15.0). Data were extracted by MRC and AFC. The following 
information was recorded for each study: first author’s name, title, year of publication, study 
design, underlying cancer, biologic drug and combinations, treatment arms, number of 
patients available for analysis, number of autoimmune events, grade of toxicity according to 
the Common Terminology Criteria for Adverse Events (CTCAE) defined by the National Cancer 
Institute, histopathological analysis, immunophenotyping analysis, therapeutic management 
and outcomes [7]. We selected reported cases fulfilling the same inclusion criteria and 
exclusion criteria used in the ICIR Registry. 
The following variables were collected: age, gender, ethnicity, country of residence, fulfilment of the 
2002/2016 criteria items [8,9], antinuclear antibodies (ANA >1/40), rheumatoid factor (RF), C3 and C4 
levels, cryoglobulins, and an estimation of systemic damage using the EULAR Sjögren's syndrome 
disease activity index (ESSDAI). Diagnostic tests for SjS (ocular tests, oral tests and salivary gland 
biopsy) were evaluated according to the recommendations of the European Community Study Group 
[10]. Disease diagnosis was defined as the time when the attending physician confirmed sicca 
syndrome or the fulfilment of the 2002/2016 criteria. Organ-specific autoimmune manifestations 
(irAEs) concomitant to sicca symptoms and developed after the initiation of cancer immunotherapies 
were also collected, and were classified in two groups: those who fit into the definitions included in 
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the ESSDAI index [11], which evaluates 12 domains or organ systems, and those who involved organs 
not included in the ESSDAI. Descriptive data are presented as mean and range for continuous variables 
and number and percentage for categorical variables.  
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RESULTS 
We identified in the ICIR Registry a total of 29 patients who were studied for a clinical suspicion of SjS 
after being treated with cancer immunotherapies. Three patients who received cancer 
immunotherapies other than ICI (trastuzumab in 2 cases, vemurafenib in 1 case) were excluded for the 
analysis. 
The baseline characteristics of the 26 patients treated with ICI are summarized in Table 1. There were 
11 (42%) women and 15 (58%) men, with a mean age at diagnosis of sicca/SjS of 63,57 years (range 
39-79 years, all but one classified as White ethnicity). A previous history of autoimmune diseases was 
recorded in 4 (15%) cases, and a family history of autoimmune disease in 2 (7%). Underlying cancer 
included lung (n=12), renal (n=7), melanoma (n=4), and other (n=3) neoplasia. Cancer 
immunotherapies consisted of monotherapy (77%) and combined regimens (23%). In those patients 
receiving monotherapy, all patients were treated with PD1/PD1-L inhibitors (nivolumab in 9, 
pembrolizumab in 7 and durvalumab in 4); no cases associated with CTLA-4 inhibitors were identified. 
Combined therapies included nivolumab combined with ipilimumab (6 cases) or pergIL10 (1 case). The 
median interval between onset of ICI treatment and sicca/SjS diagnosis was 6,5 months (range 1 to 28 
months). 
The main SjS-related features are summarized in Table 2 and consisted of dry mouth in 25 (96%) 
patients, dry eye in 17 (65%), abnormal ocular tests in 10/16 (62%) and abnormal oral diagnostic tests 
in 12/14 (86%) patients. Minor salivary gland biopsy was carried in 15 patients: histopathological 
findings consisted of mild chronic sialadenitis in 8 (53%) patients and focal lymphocytic sialadenitis 
(Chisholm-Mason classification > 3) in the remaining 7 (47%); a focus score was measured in 5 of the 
6 patients (mean of 1.8, range 1 to 4). Immunological markers included positive ANA in 13/25 (52%), 
anti-Ro/SS-A in 5/25 (20%), RF in 2/22 (9%), anti-La/SS-B in 2/25 (8%), low C3/C4 levels in 1/17 (6%) 
and positive cryoglobulins in 1/10 (10%). Classification criteria for SjS were fulfilled by 10 (62%) out of 
16 patients in whom the two key classificatory features (salivary gland biopsy and Ro autoantibodies) 
were carried out; 5 (50%) of the 10 patients fulfilled the criteria due to the histopathological findings 
in the absence of anti-Ro autoantibodies. 
Among the 26 patients, there were only 3 (11%) who presented exclusively sicca syndrome without 
organ-specific autoimmune manifestations. Among those with systemic features, 10 (43%) presented 
with features included in the ESSDAI classification, 7 (30%) with non-ESSDAI features, and the 
remaining 6 (27%) presented with both ESSDAI and non-ESSDAI features. The estimated mean total 
ESSDAI score was 10.26 (ranging between 0 and 48) and 11.68 (ranging between 0 and 56) for 
clinESSDAI. The involved organs following the ESSDAI classification consisted of features included in 
the cutaneous (n=10), articular (n=8), glandular (n=5), peripheral nerve system (n=5), constitutional 
(n=4), muscular (n=4), pulmonary (n=1), renal (n=1) and central nervous system (n=1) domains. Non-
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ESSDAI organ-specific autoimmune features included thyroiditis (n=10), enterocolitis (n=5), hepatitis 
(n=5), vitiligo (n=2), myocarditis (n=1), hypophysitis (n=1), adrenal insufficiency (n=1) and cytokine-
release syndrome (n=1). 
Therapeutic management included measures directed to treat sicca symptoms and therapies against 
autoimmune-mediated manifestations. In most patients, sicca symptoms were managed with topical 
measures, including oral pilocarpine in two cases presenting with severe oral dryness, and topical CyA 
drops in one case with severe ocular dryness; two patients received systemic corticosteroids. Sicca 
symptoms persisted in spite of using these therapies. Systemic therapy was used in 11 (42%) patients 
using first-line therapy with glucocorticoids (including methylprednisolone pulses in 2 cases, plus 
second-line therapies including hydroxychloroquine (arthritis in 2 cases) or immunosuppressive agents 
(myositis and hepatitis, respectively), and rescue therapies including intravenous 
immunoglobulins/plasma exchanges (myositis, cytokine-release syndrome), infliximab (enterocolitis) 
and tocilizumab (arthritis); therapeutic response for systemic features was observed in 8/11 (73%). No 
patient died due to autoimmune involvement. 
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DISCUSSION 
Sjögren syndrome (SjS) is a systemic autoimmune disease that mainly affects the exocrine glands. This 
leads to dryness of the main mucosal surfaces, such as the mouth, eyes, nose, pharynx, larynx and 
vagina [12]. In the etiopathogenesis of SjS, a specific combination of individual genetic predisposition 
(intrinsic factors) and environmental agents (extrinsic factors) may be central to the development of 
the disease [13]. The key SjS symptoms (oral and ocular dryness) have been also linked to a large list 
of systemic and topical drugs, mainly through their impact on lachrymal and salivary gland secretion 
[14–16]. Until the arrival of cancer immunotherapies, no association between sicca/Sjögren syndrome 
and the use of monoclonal antibodies was reported.  
Oral/ocular dryness are reported as irAE in 98/1832 (5.3%) patients with cancer treated with 
immunotherapies included in RCTs [17–21] (Table 3); the frequency was higher for patients who 
received combination therapy of checkpoint inhibitors (9.4%) and lower for patients treated with CTLA-
4 inhibitors (1.4%). No information about specific SjS evaluations was reported, and all cases but one 
were classified as CTCAE grade I-II. The ICIR Registry has identified 60 cases of sicca/Sjögren syndrome 
triggered by ICIs in patients with cancer, 34 from the SLR [5,6,22–32] and the 26 unpublished cases 
collected among ICIR centers. Among them, the 22 patients (10 from the ICIR Registry and 12 from the 
SLR) who fulfilled the current classification criteria of SjS had a very specific phenotype, clearly different 
from that observed in the idiopathic Sjögren syndrome [33] (Figure 1): 
a) The epidemiological and clinical profile seem to be quite different from primary SjS, with half 
cases being men (only 5% in primary), a mean age at diagnosis ten years older, a lower 
frequency of both oral and ocular dryness and a lower frequency of abnormal ocular tests in 
comparison with the data reported in the “idiopathic” primary SjS [33]. In addition, nearly 20% 
of cases had a history of previous autoimmune diseases (personal or familial), suggesting a 
potential predisposing immunogenetic background in some patients. 
b) The histopathological profile consisted of the typical focal lymphocytic sialadenitis of the 
primary form in half the cases biopsied [34]. In primary SjS, the median % of T-cells is around 
70% (50% CD4+, 20% CD8+) and of B cells around 22% [35,36]. By immunohistochemistry, 
Warner et al [6] have recently reported a predominant T-lymphocytic infiltrate, with a slight 
majority of CD4+ over CD8+ T cells and few CD20+ B cells. This pattern is different from 
characteristic SjS infiltrates where B cells may represent 20%–62% of all lymphocytes and FS 
directly correlating with B-cell ratios [37]. The study also reported scattered infiltrating PD-1-
positive T cells and epithelial PD-L1 positivity only in the most severely infiltrated cases. Some 
patients reported by Warner et al [6] were treated with ICI for thymic epithelial neoplasms; 
the significance of this finding is intriguing but may reflect underlying thymic dysfunction-
related autoimmunity, which was exacerbated by an ICI-augmented immune response [38]. 
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c) There was a much lower prevalence of SjS-associated serum autoantibodies (52% ANA, 20% 
Ro/SS-A, 9% RF, 8% La/SS-B) in comparison with idiopathic primary SjS. The predominant 
seronegative immunological pattern is similar to that reported for other irAEs related to cancer 
immunotherapies [31,39–41]. 
d) These patients required a more intense therapeutic management than primary SjS patients 
[42]: 20% of patients required specific therapies for severe dryness, 42% of cases required 
systemic corticosteroids, and 31% second/third line therapies for non-sicca systemic disease. 
 
The etiopathogenesis of immunotherapy-induced SjS/sicca syndrome is unknown. Probably, a specific 
genetic background that predisposes to their development could play a role. This could also contribute 
to explain the exacerbations of pre-existing SjS, reported in several patients exposed to cancer 
immunotherapies. Danlos et al [43] reported one patient who developed a relapse consisting of acute 
dermatitis and sicca syndrome, Menzies et al [44] reported a relapse in 2 patients with SjS (no further 
details), and Warner et al [6] reported dry eye or dry mouth prior to ICI treatment in 5 patients. 
Furthermore, it seems reasonable to hypothesize that patients with pre-treatment positive 
immunological markers could be more prone to develop autoimmune processes, as has been reported 
in patients with autoimmune diseases developed after TNF-targeting therapies [45]. From a 
pathogenic view, two findings should be highlighted from our results: the enhanced risk in patients 
receiving combined regimens as has been reported for other irAEs [46], and the remarkable association 
with the use of PD1 blockers (95% of reported cases of triggered SjS were exposed to these 
immunotherapies). In fact, PD-1 deficiency results in the development of fatal myocarditis in MRL mice 
due to a massive infiltration of lymphocytes in heart, with additional inflammatory foci being found in 
the liver, lung, stomach and salivary glands [47]. The close association we found between sicca/SjS and 
treatment with anti-PD1/PDL1 antibodies may help to better understanding pathophysiology of SjS. 
Like other systemic autoimmune diseases, SjS is an heterogeneous disease and a better stratification 
of patients is necessary [48]. A first effort of stratification may be to divide patients between those 
with a type 1 interferon/BAFF/ B-cell signature from those with a T-cell /NK-cell/type 2 IFN signature. 
Of note these patients cannot be separated based on the transcriptomic IFN signature since it overlaps 
between type 1 and type 2 IFN. The pattern of sicca/SjS presented by these patients with cancer 
treated with ICI suggest that the PD/PDL-1 pathway could play a role in the SjS patients with the T-
cell/NK-cell/type 2 IFN signature. 
We also found a significant overlap between some organ-specific irAEs and the clinical domains 
included into the score that measures systemic activity in primary SjS (ESSDAI), making difficult to 
consider these organ-specific features either as independente irAEs (unrelated to SjS) or as forming 
part of the triggered SjS (systemic form of the disease). This may be even more difficult when the 
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patient develop ESSDAI features highly characteristic of the disease (parotid enlargement, articular or 
cutaneous features, autoimmune neuropathies).  It is unclear whether the ESSDAI can be used in 
scoring systemic activity in patients with SjS triggered by ICI, a clinical scenario for which this score was 
not specifically designed for. Another key message is that nearly 60% of patients in whom a SjS was 
clinically suspected and that were fully evaluated for the disease (including both immunological and 
histopathological studies) fulfilled the current classification criteria for SjS. This significant percentage 
raises two questions: a) whether a history of ICI use should be included as a new exclusion criterion in 
a future review of SjS criteria, and b) whether the fulfilment or not of the current criteria could modify 
the therapeutic approach of the triggered SjS, especially of those cases presenting with systemic 
involvement.  
The retrospective design of the study means that our results need to be interpreted cautiously. The 
level of association between a drug and the induced autoimmune disease cannot be evaluated by a 
retrospective analysis of individual reported cases and should always be studied according to the 
estimated total population exposed to this agent. We cannot rule out the possibility that some cases 
may have a latent SjS, especially in women of middle-age in whom the cancer diagnosis (and the 
corresponding treatment) was coincidental with the initial development of a SjS, with the frequent 
medical visits and the enhanced medical follow-up favouring the discovery of an underlying SjS. 
Indeed, the overwhelming majority of reported cases defined the induced autoimmune disease as 
newly diagnosed, although in some cases this was not clearly stated. More importantly, a complete 
study for confirming the fulfilment of the current classification criteria for SjS (salivary biopsy + anti-
Ro determination) was carried out in only 36 cases, of whom 61% fulfilled the criteria; in nearly half 
the confirmed cases, the diagnosis was achieved with salivary biopsy in immunonegative patients. 
In spite of these limitations and the scarce quality of the available data, most of the previously reported 
recommendations for the management of patients with autoimmune diseases triggered by biological 
agents would seem to remain valid when applied to patients initiating cancer immunotherapy [49]. 
Before initiating the biological therapy, a careful pre-therapeutic evaluation paying special attention 
to pre-existing clinical or immunological autoimmune features is recommended. Discontinuation of 
biological therapy is mandatory in patients with severe involvement of internal organs, while in 
patients with sicca features, continuation could be considered (always with a closer follow-up). If they 
are diagnosed timely, most irAEs, except endocrine and some inflammatory arthritis cases, are 
reversible, requiring the use of immunosuppressive agents only in very limited cases [50]. This does 
not appear to be the case for sicca/Sjogren syndrome, whose triggered sicca symptoms 
overwhelmingly became chronic, following the same pattern of the idiopathic form of the disease. 
Therefore, corticosteroids are not recommended to treat exclusively sicca features as is recommended 
for primary SjS, and should be carefully used in patients with cancer [51,52]. Corticosteroids and/or 
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immunosuppressive agents may be required in severe cases to control the induced systemic 
manifestations of SjS despite the withdrawal of the immunotherapy. 
In summary, immune checkpoint inhibitors should be included in the large list of drugs causing sicca 
symptoms; 60% of cases fulfil the current classification criteria for primary SjS, and this triggered SjS 
should be considered a new emerging immunotherapy-triggered form of the disease. These patients 
display a very-specific profile away from that reported in idiopathic SjS, including an enhanced 
involvement of men, a higher mean age at diagnosis, a predominant immunonegative serological 
profile, and a notable development of systemic disease in spite of the poor immunological profile. The 
close association found between sicca/Sjögren syndrome and cancer immunotherapy, primarily PD1 
blockade, requires further specific investigation. 
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TABLES 
Table 1. Baseline characteristics of 26 patients treated with ICI who developed sicca/SjS included in 
the ICIR Registry. 
Table 2. The main SjS-related features of 26 patients treated with ICI who developed sicca/SjS 
included in the ICIR Registry. 
Table 3. Dryness reported as irAE in patients with cancer treated with ICI included in RCTs [17–21]. 
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Patient Gender Age at 
diagnosis 
Previous 
autoimmune 
diseases 
Underlying 
cancer 
Checkpoint inhibitor Months ICI 
stopped 
Specific sicca 
therapy 
Systemic therapy (organ involved) 
1 F 61 None Lung Nivolumab 10 No Topical No 
2 F 72 None Lung Nivolumab + ipilimumab 7 No Topical GC, IFX (colitis) 
3 M 39 None Melanoma Nivolumab + ipilimumab 1 No Topical GC, MMF (CRS) 
4 F 52 None Colon Nivolumab + ipilimumab 1 No Topical GC (hep) 
5 F 79 None Lung Pembrolizumab 1 No Topical GC, ivIG (systemic) 
6 F 71 PHEWS Melanoma Nivolumab 6 Yes Topical GC, TAC (hep) 
7 M 64 PM Lung Durvalumab 1 Yes Topical GC, MMF, IVIG, PeX (musc) 
8 M 71 None Lung Pembrolizumab 7 Yes Topical + GC No 
9 M 79 None Melanoma Pembrolizumab 28 Yes Topical + GC No 
10 F 50 None Lung Pembrolizumab 5 No Topical GC, HCQ (art) 
11 M 74 None Renal Nivolumab 11,2 No Topical GC, TCZ (art) 
12 M 77 None Renal Nivolumab 5,7 No Topical + 
cevimeline 
No 
13 M 72 None Lung Pembrolizumab 2 No None No 
14 M 70 None Lung Nivolumab 18 Yes Ocular GC/CyA No 
15 F 51 None Chordoma Durvalumab 3,7 No Topical No 
16 M 71 None Lung Nivolumab 2 No Topical No 
17 M 58 None Lung Pembrolizumab 6 No Topical No 
18 M 60 None Melanoma Durvalumab 2 No Topical GC (art) 
19 M 71 Uveitis Renal Nivolumab + pegIL10 8,3 No Topical GC (iridocyclitis) 
20 F 68 None Lung Nivolumab 6 Yes Topical No 
21 M 51 None Lung Durvalumab 3 No Topical No 
22 M 49 None Renal Nivolumab + ipilimumab 4,6 No Topical No 
23 F 56 SpA Renal Nivolumab + ipilimumab 2,4 No None No 
 19 
24 F 58 None Cervix Nivolumab 2,6 No None No 
25 M 67 None Renal Pembrolizumab 14 No None No 
26 F 62 None Renal Nivolumab 10,5 No Topical + 
pilocarpine 
GC, HCQ (art) 
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Patient Dry mouth/oral 
tests results 
Dry eye/ocular 
tests results 
Minor 
salivary 
gland 
biopsy 
(focus 
score) 
Autoantibodies 
(ANA/RF/Ro/La) 
Complement 
levels/cryoglobulins 
SjS 
criteria  
ESSDAI 
(clinESSDAI) 
Sytemic features Other irAEs 
1 Yes/abnormal Yes/abnormal NA Neg/neg/neg/neg NA/NA NA 9 (10) Cut. Musc Col 
2 Yes/abnormal Yes/normal MCS Neg/neg/neg/neg Normal/negative No 8 (9) Cut, pulm Col, thyr 
3 Yes/na Yes/na MCS Neg/neg/neg/neg Normal/NA No 0 (0) None CRS, hep 
4 Yes/abnormal Yes/abnormal NA Pos/NA/neg/neg Normal/NA NA 3 (3) Cut Hep 
5 Yes/abnormal Yes/normal MCS Pos/neg/pos/neg Normal/negative Yes 48 (56) Const, gland, art, renal, musc, 
PNS, CNS 
Hep 
6 Yes/na Yes/na NA Pos/neg/neg/neg Normal/NA NA 0 (0) None Hep, col 
7 No/normal Yes/abnormal MCS Pos/neg/neg/neg NA/NA No 18 (21) Musc Myoc, col, thyr 
8 Yes/abnormal No/normal MCS Pos/neg/neg/neg Normal/negative No 0 (0) None None 
9 Yes/abnormal No/normal FLS (1.8) Neg/neg/neg/neg Normal/NA Yes 5 (5) Const, gland None 
10 Yes/abnormal Yes/abnormal FLS (2) Pos/neg/neg/neg Normal/negative Yes 9 (12) Art, cut None 
11 Yes/na Yes/na NA Neg/neg/neg/neg NA/NA NA 4 (6) Art None 
12 Yes/na No/na NA Neg/neg/neg/neg Normal/NA NA 2 (3) Art None 
13 Yes/abnormal Yes/abnormal MCS Pos/neg/neg/neg NA/negative No 23 (26) Const, cut, musc, PNS None 
14 Yes/abnormal Yes/abnormal MCS Pos/neg/neg/neg Normal/negative No 3 (3) Cut None 
15 Yes/na No/na NA Neg/neg/neg/neg NA/NA NA 0 (0) None None 
16 Yes/abnormal Yes/na NA Pos/neg/neg/neg Normal/NA NA 0 (0) None None 
17 Yes/na No/normal NA NA/NA/NA/NA NA/NA NA 5 (5) PNS None 
18 Yes/na No/normal NA Pos/neg/pos/neg Low/pos Yes 28 (30) Art, cut, pulm, PNS Pneum, vitil 
19 Yes/na No/na FLS (1) neg/NA/neg/neg NA/NA Yes 0 (0) None Thyr, 
iridocyclitis 
 21 
20 Yes/abnormal Yes/abnormal FLS (1) Pos/neg/neg/neg Normal/negative Yes 3 (3) Cut Thyr 
21 Yes/abnormal No/abnormal FLS (4) Pos/neg/pos/pos Normal/NA Yes 3 (3) Cut Thyr 
22 Yes/na No/na NA Neg/neg/neg/neg NA/NA NA 0 (0) None Thyr, adren 
23 Yes/na Yes/normal FLS (nd) Pos/pos/pos/pos Normal/NA Yes 5 (6) Gland, art Thyr, col 
24 Yes/na Yes/abnormal MCS Neg/neg/pos/neg Normal/NA Yes 4 (5) Gland, art Thyr, hep, vitil 
25 Yes/normal Yes/abnormal FLS (1) neg/NA/neg/neg NA/negative Yes 11 (11) Const, cut, PNS Thyr, hypoph 
26 Yes/na Yes/na NA Neg/pos/neg/neg Normal/negative NA 4 (5) Gland, art Thyr, pneum 
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Authors (year) Checkpoint inhibitor Combination 
therapy 
Type of study Population 
studied 
Sicca 
cases 
% 
Hodi et al (2018) Ipilimumab   Phase III 311 7 2,25 
Robert et al (2015) Ipilimumab   Phase III 256 1 0,39 
Hodi et al (2018) Nivolumab Ipilimumab Phase III 313 19 6,07 
Hodi et al (2018) Nivolumab   Phase III 313 13 4,15 
Motzer et al (2015) Nivolumab   Phase II 167 11 6,59 
Giaccone G et al (2018) Pembrolizumab   Phase II 40 2 5,00 
Long et al (2017) Pembrolizumab ipilimumab Phase I 154 25 16,23 
Robert et al (2015) Pembrolizumab   Phase III 278 20 7,19 
TOTAL       1832 98 5,35 
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